Cancer immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has entered into a research collaboration agreement with European biopharma BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer.
The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T-cell receptors.
Moditope is a new class of potentially potent immunotherapy agents which stimulate the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.
To get a bit scientific, Moditope stimulates the production of the CD4+ T cells using tumour-associated peptide epitopes which allow the activated T cells to seek out and kill tumour cells that would otherwise have been hidden from the immune system.
Once the initial studies have been completed, BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Scancell’s Modi-1 epitopes.
“We are delighted to be working with BioNTech, one of Europe's new immuno-oncology power-houses, to investigate the development of targeted immunotherapies for the treatment of cancer,” Scancell’s chief scientific officer Lindy Durrant.
“Pre-clinical data from our Moditope platform has shown unprecedented anti-tumour effects can be delivered without the need for checkpoint inhibition.
“We believe that this, combined with BioNTech's engineered T cells specific to Moditope epitopes, could have great potential as a novel immunotherapy.”